Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression systems: An overview of the current upstream technologies

Current Pharmaceutical Biotechnology

Volumn 9, Issue 6, 2008, Pages 447-467

  Chartrain, Michel ^a   Chu, Lily ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALACTOSE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; REO PRO; RITUXIMAB; SIALIC ACID; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACTIBIX;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASTHMA; B CELL LYMPHOMA; BIOCHEMISTRY; BREAST CANCER; CELL CLONE; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COMMERCIAL PHENOMENA; COMPLEMENT DEPENDENT CYTOTOXICITY; CROHN DISEASE; DRUG INDICATION; DRUG MANUFACTURE; DRUG STRUCTURE; GENE EXPRESSION SYSTEM; GENE VECTOR; GENETIC ENGINEERING; GENETIC MANIPULATION; HUMAN; INHIBITION KINETICS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; MAMMAL CELL; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PERCUTANEOUS CORONARY INTERVENTION; PSORIASIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTE AGGREGATION INHIBITION; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; DRUG DESIGN; DRUG INDUSTRY; FORECASTING; HUMANS; IMMUNOTHERAPY; MAMMALS; PROTEIN ENGINEERING; TECHNOLOGY, PHARMACEUTICAL;

MAMMALIA;

EID: 60849120154     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920108786786367     Document Type: Review

References (197)

1. Reichert, J. and Pavlou, A. (2004) Monoclonal antibody market. Nat. Rev., 3, 383-384.
2. Reichert, J.; Rosensweig, C.; Faden, L. and Dewitz, M. (2005) Monoclonal antibody successes in the clinic. Nat. Biotechnol., 23, 1073-1078.
3. Reichert, J. and Valge-Archer, V. (2007) Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov., 6, 349-356.
4. Reichert, J. (2008) Number of mAbs entering clinical study nearly tripled in last decade. Tufts Center for Study of Drug Development Impact Report, 10(2), 1-4.
5. Arrowhead, monoclonal antibody therapies 2004. Entering a new era. Minnetonka, MN: Arrowhead Publishers.
6. Carroll, S. (2003) Development Partnerships: accelerating product development through collaborative programs. BioProcess International, 48-43.
7. Chaplin, D. (2003) Overview of the immune response. J. Allergy Clin. Immunol., 111(2), S442-S459.
8. Janeway, C.; Travers,P.; Walport, M. and Capra, D. (1999) Immunobiology. 4th ed., Elsevier, New York, NY: p. 635.
9. Bhatt, D. and Topol, E. (2002) Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discov., 2, 15-28.
10. Marasco, W. and Sui, J. (2007) The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol., 25(12), 1421-1434.
11. Wilkins, D. and Mayer, A. (2006) Development of antibodies for cancer therapy. Expert Opin. Biol. Ther., 6(8), 787-796.
12. Elfiky, A.; Saif, M. (2007) The developing trend of monoclonal antibodies in the treatment of colorectal cancer. Expert Opin. Biol. Ther., 7(6), 871-883.
13. Pankhurst, T. and Adu, D. (2004) Antibodies in the prevention of renal allograft rejection. Expert Opin. Biol. Ther., 4(2), 243-252.
14. Trikha, M.; Yan, L. and Nakada, M. (2002) Monoclonal antibodies as therapeutics in oncology. Curr. Opin. Biotechnol., 13, 609-614.
15. Andreakos, E.; Taylor, P. and Feldmann, M. (2002) Monoclonal antibodies in immune and inflammatory diseases. Curr. Opin. Biotechnol., 13, 615-620.
16. Sandborn, W.; Faegan, B.; Stoinov. S.; Honiball, P. Rutgeerts, P.; Mason D.; Bloomfield, R. and Schrieber, S. (2007) Certolizumab Pegol for the treatment of Crohn's disease. N. Eng. J. Med., 357, 228-238.
17. Salfeld, J. (2007) Isotype selection in antibody engineering. Nat. Biotechnol., 25(12), 1369-1372.
18. Jefferis, R. (2005) Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog., 21,11-16.
19. Jefferis, R. (2006) Criteria for selection of IgG isotype and glycoform of antibody therapeutics. BioProcess International, 40-43.
20. Satho, M.; Iida, S. and Shitara, K. (2006) Non-fucosylated therapeutic antibodies as next generation therapeutic antibodies. Expert Opin. Biol. Ther., 6(11), 1161-1173.
21. Kanda, Y.; Imai-Nishiya, H.; Kuni-Kamochi, R.; Mori, K.; Inoue, M.; Kitajima-Miyama, K.; Okazaki,A.; Iida, S.; Shitara, K. and Satoh, M. (2007) Establishment of a GDP-mannose 4,6-dehydratase (GDM) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics. J. Biotechnol., 130, 300-310.
22. Yamane-Ohnuki, N.; Kinoshita, S.; Inoue-Urakabo, M.; Kusunoki, M.; Lida, S.; Nakano, R.; Wakitani, M.; Niwa, R.; Sakadura, M.; Uchida, K.; Shitara, K. and Satoh, M. (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng., 87, 614-622.
23. Kanda, Y.; Yamane-Ohnuki, N.; Sakai, N.; Yamano, K.; Nakano, R.; Inoue, M.;. Misaka, H.; Iida, S.; Wakatini, M.; Konno, Y.; Yano, K.; Shitara, K.; Hosoi, S., Satoh, M. (2006) Comparison of cell lines for stable production of fucose-negative antibodies with enhances ADCC. Biotechnol. Bioeng., 94(4), 680-688.
24. Shinkawa, T.; Nkamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakarada, M.; Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M.; Hanai, N. and Shitara, K. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucoseamine of human IgG1 complex type oligosaccharides shows the critical role of enhancing antibody-dependant cellular cytotoxicity. J. Biol. Chem., 278, 3466-3473.
25. Shields, R.; Lai, J. Keck, R.; O'Connell, L.; Hong, K.; Meng, G.; Weikert, S. and Presta, L. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J. Biol. Chem., 277, 26733-26740.
26. Mori, K.; Kuni-Kamochi, R.; Yamane-Ohnuki, N.; Wakitani, M.; Yamano, K.; Imai, H.; Kanda, Y.; Niwa, R.; Lida, S.; Uchida, K.; Shitara, K.and Satoh, M. (2004) Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol. Bioeng., 88, 901-908.
27. Schuster, M.; Umana, P.; Ferrara, C.; Brunker, P.; Gerdes, C.; Waxenecker, G.; Wiederkum, S.; Schwager, C.; Loibner, H.; Himmler, G. and Mudde, G. (2005) Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res., 65, 7934-7941.
28. Davies, J.; Jiang, L.; pan, L.; LaBarre, M.; Anderson, D. and Reff, M. (2001) Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcgRIII. Biotechnol. Bioeng., 74, 288-294.
29. Ferrara, C.; Brunker, P.; Suter, T.; Moser, S.; Puntener, U. and Umana, P. (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme location domain and co-expression of heterologous beta 1, 4-N-acetlyglucoseaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng., 93(5), 851-861.
30. Boyd, P.; Lines, A. and Patel, A. (1995) The effect of removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol., 32, 1311-1318.
31. Wildt, S. and Gerngross, T. (2005) The humanization of N-glycosylation pathways in yeast. Nat. Rev. Microbiol., 3, 119-128.
32. Gerngross, T. (2004) Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat. Biotechnol., 22(11), 1409-1414.
33. Hamilton, S. and Gerngross, T. (2007) Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr. Opin. Biotechnol., 18, 387-392.
34. Chaplin, D. (2003) Overview of the immune response. J.Allergy Clin. Immunol., 111(2 Suppl.), 442-459.
35. Kohler, G. and Milstein, C. (1975) Continuous culture of fused cells secreting antibody of predefined specificity. Nature, 265, 495-497.
36. Kohler, G. and Milstein, C. (1976) Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol., 6, 511-519.
37. Kohler, G.; Howe, S. and Milstein, C. (1976) Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur. J. Immunol., 6, 292-295.
38. Freshney, I. (2000) Production of monoclonal antibodies, in Culture of animal cells, a manual of basic technique, Wiley and Sons: New York, NY, pp. 452-455.
39. Stacey, A. (2000) Animal cell types, hybridoma cells, in Encyclopedia of cell technology, (Speir, R. Ed.), J. Wiley and Sons: New York, NY, 83-89.
40. Szybalski, W. (1992) Use of the HPRT gene and the HAT selection technique in DNA mediated transformation of mammalian cells: first steps towards developing hybridoma techniques and gene therapy. BioEssays, 14(7), 495-500.
41. Roskos, L.; Davis, C. and Schwab, G. (2004) The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev. Res., 61, 108-120.
42. Yamashita, M.; Katakura, Y. and Shirahata, S. (2007) Recent advances in the generation of human monoclonal antibody. Cytotechnology, 55, 55-60.
43. Mazor, Y.; Van Blarcom, T.; Mabry, R.; Iverson, B. and Georgiou, G. (2007) Isolation of engineered, full-length antibodies for libraries expressed in Escherichia coli. Nat. Biotechnol., 25(5), 563-565.
44. Sidhu, S. (2007) Full-length antibodies on display. Nat. Biotechnol., 25(5), 537-538.
45. Carter, P. (2006) Potent antibody therapeutics by design. Nat. Rev. Immunol., 6, 343-357.
46. Kipriyanov, S. and Little, M. (1999) Generation of recombinant antibodies. Mol. Biotechnol., 12,173-201.
47. Benhar, I. (2007) Design of synthetic antibody libraries. Expert Opin. Biol. Ther., 7(5), 763-779.
48. Jakobovits, A.; Amado, R.; Yang, X.; Roskos, L. and Schwab, G. (2007) From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol., 25(10), 1134-1143.
49. Jain, M.; Kamal, N. and Batra, S. (2007) Engineering antibodies for clinical applications. Trends Biotechnol., 25(7), 307-316.
50. Makrides, S.C. (2003) Vectors for gene expression in mammalian cells, in Gene transfer and expression in mammalian cells, (Makrides, S.C., Ed.), Elsevier: Amsterdam, pp. 9-26.
51. Wurm, F. and Jordan, M. (2003) Gene transfer and gene amplification in mammalian cells, in Gene transfer and expression in mammalian cells, (Makrides, S.C., Ed.), Elsevier: Amsterdam, pp. 307-335.
52. Colosimo, A.; Goncz, K.; Holmes, A.; Kunzelmann, K.; Novelli, G.; Malone, R.; Bennett, M. and Gruenert, D. (2000) Transfer and expression of foreign genes in mammalian cells. Biotechniques, 29(2), 314-331.
53. Schlatter, S.; Stansfield, S.; Dinnis, D.; Racher, A.; Birch, J. and James, D. (2005) On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechol. Prog., 21, 122-133.
54. Weber, W. and Fussenegger, M. (2003) Inducible gene expression in mammalian cells, in Gene transfer and expression in mammalian cells, (Makrides, S.C., Ed.), Elsevier: Amsterdam, pp. 589-604.
55. Kwaks, T. and Otte, A. (2006) Employing epigenetics to augment the expression of therapeutic proteins in mammalian cells. Trends Biotechnol., 24(3), 137-142.
56. Baer, A. and Bode, J. (2001) Coping with kinetic and thermodynamic barriers: RMCE, an efficient strategy for the targeted integration of transgenes. Curr. Opin. Biotechnol., 12, 473-480.
57. Kwaks, T.; Barnett, P.; Hemrika, W.; Siersma, T.; Sewalt, R. Satijn, D.; Brons, J.; van Blokland, R.; Kruckeberg, A.; Kelder, A. and Otte, W. (2003) Identification of anti-repressor elements that confer high and stable protein production in mammalian cells. Nat. Biotechnol., 21, 553-558.
58. Girod, P.; Zahn-Zabal, M. and Mermod, N. (2005) MAR elements as tools to increase protein production by CHO cells, in Animal cell technology meets genomics, (Godia, M.F. and Fussenegges, M., Ed.), Springer: Amsterdam, pp. 411-415.
59. Girod, P.; Zahn-Zabal, M. and Mermod, N. (2005) Use of the chicken lysozyme 5′ matrix attachment region to generate high producer CHO cell lines. Biotechnol. Bioeng., 91(1), 1-11.
60. Benton, T.; Chen, T.; McEntree, M.; Fox, B.; King, D.; Crombie, R.; Thomas, T. and Bebbington, C. (2002) The use of UCOE vectors in combination with a preadapted serum free, suspension cell line allows for rapid production of large quantities of protein. Cytotechnology, 38, 43-46.
61. Barnes, L.; Bentley, C. and Dickson, A. (2000) Advances in animal cell recombinant protein production: GS-NS0 expression system. Cytotechnology, 32, 109-123.
62. Kearney, J.; Radbruch, A.; Liesegang, B. and. Rajewsky, K. (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol., 123(4), 1548-1550.
63. Galfre, G. and Milstein, C. (1981) Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol., 73, 3-75.
64. Shulman, M.; Wilde, C. and Kohler, G. (1978) A better cell line for making hybridomas secreting specific antibodies. Nature, 276,209-210.
65. Potter, M. (1972) Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol. Rev., 52(3), 632-719.
66. Sato, J.; Cao, H-T.; Kayada, Y.; Cabot, M.; Sato, G.; Okamoto, T. and Welsh, C. (1988) Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium. In Vitro Cell Dev. Biol., 24,1223-1228.
67. Sato, J.; Kawamoto, T. and Okamoto, T. (1987) Cholesterol requirement of P3-X63-Ag8 and X63-Ag8.653 mouse myeloma cells for growth in vitro. J. Exp. Med., 165, 1761-1766.
68. Sato, J.D.; Kawamoto, T.; McClure, D.B.; Sato, G.H. (1984) Cholesterol requirement of NS-1 mouse myeloma cells for growth in serum-free medium. Mol. Biol. Med., 2(2), 121-34.
69. Chen, J.-K.;. Li, L. (1987) Sterol depletion reduces receptor-mediated low-density lipoprotein binding in NS-1 mouse myeloma cells. Exp. Cell Res., 117, 76-85.
70. Chen, J.-K.; Okamoto, T.; Sato, J.; Sato, G. and McClure, D. (1986) Biochemical characterization of the cholesterol-dependent growth of the NS-1 mouse myeloma cell line. Exp. Cell Res., 163, 117-126.
71. Gorfien, S.; Paul, B.; Walowitz, J.; Keem, R.; Biddle, W. and James, D. (2000) Growth of NS0 cells in protein-free, chemically defined medium. Biotechnol. Prog., 16, 682-687.
72. Walowitz, J.; Fike, R. and Jayme, D. (2003) Efficient lipid delivery to hybridoma culture by use of cyclodextrin in a novel granulated dry-form medium technology. Biotechnol. Prog., 19(1), 64-8.
73. Keen, M. and Steward, T. (1995) Adaptation of cholesterol-requiring NS0 mouse myeloma cells to high density growth in a fully defined protein-free and cholesterol-free culture medium. Cytotechnology, 17, 203-211.
74. Kawamoto, T., Sato, J.; Le, A.; McClure, D. and Sato, G. (1983) Development of a serum-free medium for growth of NS-1 mouse myeloma cells and its application to the isolation of Ns-1 hybridomas. Anal. Biochem., 130, 445-453.
75. Birch, J.; Boraston, R.; Metcalfe, H.; Brown, M.; Bebbington, C. and Field, R. (1994) Selecting and designing cell lines for improved physiological characteristics. Cytotechnology, 15, 11-16.
76. Seth, G.; Philp, R.; Denoya, C.; McGrath, K.; Stutzman-Engwall, K.; Yap, M. and Hu, W-S. (2005) Large-scale gene expression analysis of cholesterol dependence in NS0 cells. Biotechnol. Bioeng., 90, 552-567.
77. Seth, G.; Ozturk, M. and Hu, W-S, (2006) Reverting cholesterol auxotrophy of NS0 cells by altering epigenetic gene silencing. Biotechnol. Bioeng., 93(4), 820-827.
78. Seth, G.; McIvor, S. and Hu, W-S. (2006) 17-B-hydroxysteroid dehydrogenase type 7 (Hsd17b7) reverts cholesterol auxotrophy in NS0 cells. J. Biotechnol., 121, 241-252.
79. Hartman, T. Sar, N.; Genereux, K.; Barrit, D.; He, Y.; Burky, J.; Wesson, M.; Yun-Tso, J.; Tsurushita, N.; Zhou, W. and Sauer, P. (2007) Derivation and characterization of cholesterol-independent non-GS NS0 cell lines for production of recombinant antibodies. Biotechnol. Bioeng., 96(2), 294-306.
80. Raju, S. (2003) Glycosylation variations with expression systems. BioProcess International, 44-53.
81. Chung, C.H.; Mirakhur, B.; Chan, E.; Le, Q.T.; Berlin, J.; Morse, M.; Murphy, B.A.; Satinover, S.M.; Hosen, J.; Mauro, D.; Slebos, R.J.; Zhou, Q.; Gold, D.; Hatley, T.; Hicklin, D.J. and Platts-Mills, T.A. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-a-galactose. N. Engl. J. Med., 358(11), 1109-1117.
82. Bebbington, C.; Renner, G.; Thomson, S.; King, D.; Abrams, D. and Yarranton, G. (1992) High-level expression of a recombinant antibody from myeloma cells using a glutamine synthase gene as an amplifiable selectable marker. Biotechnology, 10,169-175.
83. Mulligan, R. and Berg, P. (1981) Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. PNAS, 78(4), 2072-2076.
84. Puck, T. (1985) Development of the Chinese hamster ovary (CHO) cell for use in somatic cell genetics, in Molecular cell genetics, (Gottesman, M., Ed.), Wiley and Sons: New York, pp. 37-64.
85. Puck, T.; Cieciura, S. and Robinson, A. (1958) Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects. J. Exp. Med., 108, 945-958.
86. Kao, F. and Puck, T. (1967) Genetics of somatic mammalian cells. IV. Properties of Chinese hamster cell mutants with respect to the requirement for proline. Genetics, 55, 513-524.
87. Kao, F. and Puck, T. (1968) Genetics of somatic mammalian cells. IVI. Induction and isolation of nutritional mutants in Chinese hamster cells. Proc. Natl. Acad. Sci, USA, 60, 1275-1281.
88. Urlaub, G. and Chasin, L. (1980) Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. USA, 77(7), 4216-4220.
89. Urlaub, G.; Kas, E.; Carothers, A. and Chasin, L. (1983) Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells. Cell, 33(2), 405-412.
90. Urlaub, G.; Mitchell, P.; Kas, E.; Chasin, L.; Funanage, V.; Myoda, T. and Hamlin, J. (1986) Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat. Cell Mol. Genet., 12(6), 555-66.
91. Kaufman, R.; Wasley, L.; Spiliotes, A.; Gossels, S.; Latt, S.; Larsen, G.; and Kay, R. (1985) Co amplification and co expression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells. Mol. Cell Biol., 5(7), 1750-1759.
92. Kaufman, R.; Sharp, P. (1982) Amplification and expression of sequences Co transfected with a modular dihydrofolate reductase complementary DNA gene. J. Mol. Biol., 159, 601-621.
93. Sautter, K.; Enenkel, B. (2005) Selection of high-producing CHO cells using NPT selection marker with reduced enzyme activity. Biotechnol. Bioeng., 89(5), 530-538.
94. Aldrich, T.; Viaje, A. and Morris, A. (2003) EASE vectors for rapid stable expression of recombinant antibodies. Biotechnol. Prog., 19, 433-1438.
95. Cramer, S.; van Ormondt, J.; van der Eb, H.; Valerio, J. and Hoeben, D. (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication competent adenoviruses. Hum. Gene Ther., 19, 163-168.
96. Jones, D.; kroos, N.; Anema, R.; van Montford, B.; Vooys, A.; van der Kraats, S.; van der Helm, E.; Smits, S.; Schouten, J.; Brouwer, K.; Lagerwerf, F.; van Berkel, P.; Opstelten, D-J.; Logtenberg, T. and Bout, A. (2003) High-Level expression of recombinant IgG in the human cell line PER C6. Biotechnol. Prog., 19, 163-168.
97. Yallop, C.; Maamsman, M.; Zuijderwijk, M.; van Noordenburg, Y.; Vooys, A.; Keehnen, R.; van Montfort, B.; Jansen, M.; Lagetrwerf, F.; Dijkstra, R.; Birrento, M.; de Vocht, M.; Renger, S.; Bout, A. and Opstelten, D. (2005) High level production of recombinant IgG in the human cell line PER.C6, in Animal cell technology meets genomics, (Godia, F. and Fussenegger, M., Eds.), Springer: Amsterdam.
98. Browne, S. and Al-Rubeai, M. (2007) Selection methods for high-producing mammalian cell lines. Trends Biotechnol., 25(9), 425-432.
99. Carroll, S. and Al-Rubeai, M. (2004) The selection of high-producing cell lines using flow cytometry and cell sorting. Expert Opin. Biol. Ther., 4(11), 1821-1829.
100. Bohm, E.; Voglauer, R. (2004) Steinfellner, W.; Kuner, R.; Borth, N. and Katinger, H. Screening for improved cell performance: selection of subclones with altered production kinetics or improved stability by cell sorting. Biotechnol. Bioeng., 88(6), 699-705.
101. Yoshida, T. (2001) Flow cytometry: an improved method for the selection of highly productive gene-amplified CHO cells using flow cytometry. Biotechnol. Bioeng., 74, 435-442.
102. DeMaria, C.; Cairns, V.; Schwartz, C.; Zhang, J.; Guering, M.; Zuena, E.; Estes, S. and Karey, K. (2007) Accelerated clone selection for recombinant CHO cells using a FACS-based hight-throuput screen. Biotechnol. Prog., 23, 465-472.
103. Burke, J. and Mann, C. (2006) Rapid isolation of monoclonal antibody producing cell lines. BioProcess International, 48-51.
104. Hanania, E.; Fieck, A.; Stevens, J.; Bodzin, L.; Palsson, B. and Koller, M. (2005) Automated in situ measurement of cell-specific antibody secretion and laser mediated purification for rapid cloning of highly-secreting producers. Biotechnol. Bioeng., 91(7), 872-876.
105. Clarke, S.; Dillon, J.; Smith, A. and Sotheran, E. (2004) Strategies for producing commercial cell lines. BioProcess International, 48-52.
106. Gresh, O. and Bruenker, H-G. (2006) Efficient small-scale production of proteins. The BioPharm International Guide, 6-10.
107. Kunert, R.; Wolbank, S.; Chang, M.; Voglauer, R.; Borth, N. and Katinger, H. (2004) Control of key parameters in developing mammalian production clones. BioProcess International, 54-59.
108. Birch, J.; Mainwaring, D.and Racher, A. (2005) Use of glutamine synthetase (GS) expression system for the rapid development of highly productive mammalian cell processes, in Modern biopharmaceuticals, (Knablein, J., Ed.), Wiley-Vch: Weinheim.
109. Berthold, W. (1993) Gene stability in mammalian cell and protein consistency. Biologicals, 21, 95-100.
110. Barnes, L.; Bentley, C. and Dixon, A. (2004) Molecular definition of predictive indicators of stable protein expression in recombinant NS0 myeloma cells. Biotechnol. Bioeng., 85(2), 115-121.
111. Strutzenberger, K.; Borth, N.; Kunert, R.; Steinfellner, W. and Katinger, H. (1999) Changes during sub-clone development and ageing of human antibody-producing recombinant CHO cells. J. Biotechnol., 69, 215-226.
112. Barnes, L.; Bentley, C.and Dickson, A. (2003) Stability of protein production from recombinant mammalian cells. Biotechnol. Bioeng., 81, 631-639.
113. Barnes, L.; Bentley, C. and Dickson, A. (2001) Characterization of the stability of recombinant protein production in the GS-NSO expression system. Biotechnol. Bioeng., 73(4), 261-270.
114. Barnes, L.; Moy, N. and Dickson, A. (2006) Phenotypic variations during cloning procedures: analysis of the growth behavior of clonal lines. Biotechnol. Bioeng., 94(3), 530-537.
115. Vaccaro, C.; Zhou, J.; Ober, R. and Ward, S. (2005) Engineering the Fc region of the immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol., 23(10), 1283-1288.
116. Shields, R. (2001) High resolution mapping of the binding sites on human IgG1 for FcgR1, FcgRII, FcgRIII, FcRn, and design of IgG1 variants with improved binding to the FcgR. J. Biol. Chem., 276, (6591-6604).
117. Dall'Ozzo, S.; Tartas, S.; Paintaud, G.; Cartron, G.; Colombat, P.; Bardos, P.; Watier, H. and Thibault, G. (2004) Rituximab-dependent cytoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res., 64, 4664-4669.
118. Singh, R.; Al-Rubai, M.; Gregory, C. and Emery, A. (1994) Cell death in bioreactors: a role for apoptosis. Biotechnol. Bioeng., 44, 720-726.
119. Laken, H. and Leonard, M. (2001) Understanding and modulating apoptosis in industrial cell culture. Curr. Opin. Biotech., 12, 175-179.
120. Arden, N.T.N. and Bentenbaugh, M. (2004) Cell engineering blocks cell stress and improves biotherapeutic production. Bioprocessing Journal, 23-28.
121. O'Connor, K.; Muhitch, J.; Lacks, D. and Al-Rubeai, M. (2006) Modeling suppression of cell death by Bcl-2 over-expression in myeloma NS0 6A1 cells. Biotechnol. Lett., 28, 1919-1924.
122. Tey, B. R.S.; Piredda, L. and Al-Rubeai, M. (2000) Bcl-2 mediated suppression of apoptosis in myeloma NS0 cultures. J. Biotechnol., 79, 147-159.
123. Lim, S.; Chuan, K.; Liu, S.; Loh, O.; Chung, B.; Ong, C. and Song, Z. (2006) RNAi suppression of BAx and Bak enhances viability in fed-batch cultures of CHO cells. Metab. Eng., 8, 509-522.
124. Choi, S.; Rhee, W.; Kim, E. and Park, T. (2006) Enhancement of recombinant protein production in Chinese hamster ovary cell through anti-apoptosis engineering using 30Kc6 gene. Biotechnol. Bioeng., 95(3), 459-467.
125. Crea, F.; Sarti, D.; Falcani, F.and Al-Rubeai, M. (2006) Over-expression of hTERT in CHO K1 results in decreased apoptosis and reduced serum dependency. J. Biotechnol., 121, 109-123.
126. Wong, D.; Wong, K.; Nissom, P.; Heng, C. and Yap, M. (2006) Targeting early apoptotic genes in batch and fed-batch CHO cell cultures. Biotechnol. Bioeng., 95(3), 350-361.
127. Arden N. (2006) Regulating apoptosis in mammalian cell cultures. Cytotechnology, 50, 77-92.
128. Barnes, L. and Dickson, A. (2006) Mammalian cell factories for efficient and stable protein expression. Curr. Opin. Biotech., 17, 381-386.
129. Smales, C.; Dinnis, D.; Stansfield, S.; Alete, D.; Sage, E.; Birch, J.; Racher, A.; Marshall, C. and James, D. (2004) Comparative proteomic analysis of GS-NS0 murine myeloma cell lines with varying recombinant monoclonal antibody production rate. Biotechnol. Bioeng., 88, 474-488.
130. Dinnis, D. and James, D. (2005) Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature? Biotechnol. Bioeng., 91(2), 180-189.
131. Schroder, M. (2008) Engineering eukaryotic protein factories. Biotechnol. Lett., 30, 187-186.
132. Cudna, R. and Dickson, A. (2003) Endoplasmic reticulum signaling as a determinant of recombinant protein expression. Biotechnol. Bioeng., 81, (156-65).
133. Barnes, D. and Sato, G. (1980) Serum-free cell culture: a unifying approach. Cell, 22, 649-655.
134. Ertola, R.J.; Giulietti, A.M. and Castillo, F.J. (1995) Design, formulation, and optimization of media. Bioprocess Technology, 21, 89-137.
135. Jayme, D.W. and Blackman, K.E. (1985) Culture media for propagation of mammalian cells, viruses, and other biologicals. Biotechnology Processes, 5, 1-30.
136. Jayme, D.W. (1991) Nutrient optimization for high density biological production applications. Cytotechnology, 5, 15-30.
137. Zhang, J. and Robinson, D. (2005) Development of animal-free, protein-free an chemically-defined media for NS0 cell culture. Cytotechnology, 48, 59-74.
138. Burteau, C.; Verhoeye, F.; Mols, J.; Ballez, J.; Agathos, S. and Schneider, Y-J. (2003) Fortification of a protein-free cell culture medium with plant peptones improves cultivation and productivity of an interferon-gamma-producing CHO cell line. In Vitro Cell Dev. Biol. Anim., 39(7), 291-296.
139. Chun, B-H.; Kim, J-H.; Lee, H-J. and Chung. N. (2007) Usability of size-excluded fractions of soy protein hydrolysates for growth and viability of Chinese hamster ovary cells in protein-free suspension culture. Bioresour. Technol., 98, 1000-1005.
140. Heidemann, R.; Zhang, C.; Qi, H.; Rule, J.; Rozales, C.; Park, S.; Chuppa, S.; Ray, M.; Michaels, J.; Konstantinov, K. and Naveh, D. (2000) The use of peptones as medium additives for the production of a recombinant therapeutic protein in high density perfusion cultures of mammalian cells. Cytotechnology, 32, 157-167.
141. Luo, Y. and Chen, G. (2007) Combined approach of NMR and chemometrics for screening peptones used in cell culture medium for the production of a recombinant therapeutic protein. Biotechnol. Bioeng., 92(6), 1654-1659.
142. Mols, J.; Peeters-Joris, C.; Wattiez, R.; Agathos, S. and Schneider. Y-J. (2005) Recombinant interferon-g secreted by Chinese hamster ovary-320 cells cultivated in suspension in protein-free media is protected against extracellular proteolysis by the expression of natural protease inhibitors and by the addition of plant protein hydrolysates to the culture medium. In Vitro Cell Dev. Biol. Anim., 41, 83-91.
143. Schlaeger, E.J. (1996) The protein hydrolysate, Primatone RL, is a cost-effective multiple growth promoter of mammalian cell culture in serum-containing and serum-free media and displays anti-apoptosis properties. J. Immunol. Methods, 194(2), 191-9.
144. Spens, E. and Haggstrom, L. (2007) Defined protein and animal component-free NS0 fed-batch culture. Biotech. Bioeng., 98(6), 1183-1194.
145. Heidemann, R.; Mered, M.; Wang, D.; Gardner, B.; Zhang, C.; Michaels, J.; Henzler, H-J.; Abbas, N. and Konstantinov. K. (2002) A new seed-train expansion method for recombinant mammalian cell lines. Cytotechnology, 38, 99-108.
146. Hardy, J. and Priester, P. (2004) Considerations for use of disposable technology in contract manufacturing. BioProcess International, 32-55.
147. Ninomiya, N.; Shirahata, S.; Murakami, H. and Sugahara. T. (1991) Large-scale, high-density freezing of hybridomas and its application to high-density culture. Biotech. Bioeng., 38(9), 1110-1113.
148. Lao, M.-S. and Toth, D. (1997) Effects of ammonium and lactate on growth and metabolism of a recombinant Chinese hamster ovary cell culture. Biotech. Prog., 13, 688-691.
149. Burky, J.; Wesson, M.; Young, A.; Farnsworth, S.; Dionne, B.; Zhu, Y.; Hartman, T.; Qu, L.; Zhou, W. and Sauer. P. (2007) Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies. Biotechnol. Bioeng., 96(2), 281-293.
150. Altman, P.L. and Dittmer, D.S. (1971) Handbook of Respiration and Circulation, Bethesda, MD: Federation of American Society for Experimental Biology.
151. 2 in large-scale and high-density CHO cell perfusion culture. Cytotechnology, 22, 65-78.
152. Moore, A.; Mercer, J.; Dutina, G.; Donahue, C.; Bauer, K.; Mather, J.; Etcheverry, T. and Ryll, T. (1997) Effects of temperature shift on cell cycle, apoptosis, and nucleotide pools in CHO cell batch cultures. Cytotechnology, 23, 47-54.
153. Kaufmann, H.; Mazur, X.; Fussenegger, M. and Bailey. J. (1999) Influence of low temperature on productivity, proteome, and protein phosphorylation of CHO cells. Biotechnol. Bioeng., 63(5), 573-582.
154. Hendrick, V.; Vinnepenninckx, P.; Abdelkafi, C.; Vandeputte, O.; Cherlet, M.; Marique, T.; Renemann, G.; Loa, A.; Kretzmer, G.and Werenne, J. (2001) Increased productivity of recombinant tissue plasminogen activator (t-PA) by butyrate and shift of temperature: a cell cycle phases analysis. Cytotechnology, 36, 71-83.
155. Yoon, S.K.; Kim, S.H. and Lee, G.M. (2003) Effect of low culture temperature on specific productivity and transcription level of anti-4-1BB antibody in recombinant Chinese hamster ovary cells. Biotechnol. Prog., 19, 1383-1386.
156. Yoon, S.K.; Song, J.Y. and Lee, G.M. (2003) Effect of low culture temperature on specific productivity, transcription level, and heterogeneity of erythropoietin in Chinese hamster ovary cells. Biotechnol. Bioeng., 92(3), 289-298.
157. Yoon, S.K.; Hwang, S.O. and Lee, G.M. (2004) Enhancing effect of low culture temperature on specific antibody productivity of recombinant Chinese hamster ovary cells: clonal variation. Biotechnol. Prog., 20, 1683-1688.
158. Mostafa, S.S. and Gu, X. (2003) Strategies for improved dCO2 removal in large-scale fed-batch cultures. Biotechnol. Prog., 19, 45-51.
159. 2 accumulation by eliminating bicarbonate addition to high cell-density cultures. Biotechnol. Bioeng., 96(6), 1107-1117.
160. 2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: a case study. Biotechnol. Prog., 21, 70-77.
161. Zhou, W.; Bibila, T.; Glazomitsky, K.; Montallo, J.; Chen, C.; Distefano, D.; Munshi, S.; Robinson, D.; Buckland, B. and Aunins. J. (1996) Large scale production of recombinant mouse and rat growth hormone by fed-batch GS-NS0 cell cultures. Cytotechnology, 22, 239-250.
162. Aunins, J. and Henzler, H.-J. (1993) Aeration in cell culture bioreactors, in Biotechnology: A multi-volume comprehensive treatise, (Stephanopoulos, G.; Rehm, H.J.; Reed, G.; Puhler, A.; Stadler, P.J.W., Eds.), VCH Verlag: Weinham, Germany.
163. 2 concentrations on NS0 cell culture fermentations. in Cell Culture Engineering, X. Whistler, BC, Canada.
164. Ma, N.; Chalmers, J.; Aunins, J.; Zhou, W. and Xie, L. (2004) Quantitative studies of cell-bubble interactions and cell damage at different pluronic F-68 and cell concentrations. Biotechnol. Prog., 20, 1183-1191.
165. Ma, N.; Koelling, K.W. and Chalmers, J.J. (2002) Fabrication and use of a transient contractional flow device to quantify the sensitivity of mammalian and insect cells to hydrodynamic forces. Biotechnol. Bioeng., 80(4), 428-437.
166. Mollet, M.; Godoy-Silva, R.; Berdugo, C. and Chalmers. J. (2007) Acute hydrodynamic forces and apoptosis: a complex question. Biotechnol. Bioeng., 98(4), 772-788.
167. Mollet, M.; Ma, N.; Mao, Y.; Brodkey, R.; Taticek, R. and Chalmers. J. (2004) Bioprocess equipment: characterization of energy dissipation rate and its potential to damage cells. Biotechnol. Prog., 20, 1437-1448.
168. van der Pol, L. and Tramper, J. (1998) Shear sensitivity of animal cells from a culture medium perspective. Trends Biotechnol., 16,. 323-328.
169. Bibila, T. and Robinson, D. (1995) In pursuit of the optimal fedbatch process for monoclonal antibody production. Biotechnol. Prog., 11, 1-13.
170. deZengotita, V.; Miller, W.; Aunins, J. and Zhou. W. (2000) Phosphate feeding improves high-cell-concentration NS0 myeloma culture performance for monoclonal antibody production. Biotechnol. Bioeng., 69(5), 566-576.
171. Portner, R.; Schwabe, J.-O and Frahm, B. (2004) Evaluation of selected control strategies for fed-batch cultures of a hybridoma cell line. Biotechnol. Appl. Biochem., 40, 47-55.
172. Xie, L.; Nyberg, G.; Gu, X.; Li, H.; Mollborn, F. and Wang, D. (1997) Gamma-interferon production and quality in stoichiometric fed-batch cultures of Chinese ovary (CHO) cells under serum-free conditions. Biotechnol. Bioeng., 56(5), 577-582.
173. Altamirano, C.; Cairo, J.J. and Godia, F. (2001) Decoupling cell growth and product formation in Chinese hamster ovary cells through metabolic control. Biotechnol. Bioeng., 76(4), 351-360.
174. Clark, K.; Griffiths, J.; Bailey, K. and Harcum, S. (2005) Gene-expression profiles for five key glycosylation genes for galactose-fed CHO cells expressing recombinant IL-4/13 cytokine trap. Biotechnol. Bioeng., 90(5), 568-577.
175. Genzel, Y.; Ritter, J.; Konig, S.; Alt, R. and Reichl. U. (2005) ubstitution of glutamine by pyruvate to reduce ammonia formation and growth inhibition of mammalian cells. Biotechnol. Prog., 21, 58-69.
176. Maranga, L. and Goochee, C.F. (2006) Metabolism of PER.C6 cells cultivated under fed-batch conditions at low glucose and glutamine levels. Biotechnol. Bioeng., 94(1), 139-150.
177. Petch, D. and Butler, M. (1996) The effect of alternative carbohydrates on the growth and antibody production of a murine hybridoma. Appl. Biochem. Biotechnol., 59(1), 93-104.
178. Wong, D.; Wong, K.; Goh, L.; Heng, C. and Yap. M. (2004) Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol. Bioeng., 89(2), 164-177.
179. Griffiths, J. (1990) Perfusion systems for cell cultivation, in Large scale mammalian cell culture technology, (Lubiniecki, A.S., Ed.), Marcel-Dekker Inc., New York.
180. Mizrahi, A. (1989) Techniques and equipment for animal cell cultivation, in Advances in animal cell biology and technology for bioprocesses, (Spier, R.E., Griffiths, J.B.; Stephenne, J. and Crooy, P.J. Ed.), Butterworth-Heinemann: Oxford, UK.
181. Spier, R.; Griffiths, J.; Stephenne, J. and Crooy, P. (2003) Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnol. Bioeng., 82(7), 751-765.
182. Boedeker, B.; Newcomb, R.; Yuan, P.; Braufman, A. and Kelsey. W. Production of recombinant factor VIII from perfusion cultures: I. Large scale fermentation, in Animal cell technology: products of today, prospects of tomorrow, (Spier, R.E.; Griffiths, J. and Berthold, W., Eds.), 1994, Butterworth-Heinemann: Oxford, UK.
183. Chisti, Y. (1993) Animal cell culture in stirred bioreactors: Observations on scale-up. Bioprocess Biosyst. Eng., 9(5), 191-196.
184. Cherry, R.S. and Papoutsakis, E.T. (1986) Hydrodynamic effects on cells in agitated tissue culture reactors. Bioprocess Biosyst. Eng., 1(1), 29-41.
185. Arathoon, W.R. and Birch, J. (1986) Large-scale cell culture in biotechnology. Science, 232(4756), 1390-1395.
186. Varley, J. and Birch, J. (1999) Reactor design for large scale suspension animal cell culture. Cytotechnology, 29(3), 177-205.
187. Tong, J.; Kettel. M.; Perry, E.; Pain, D.; Valentine, D.; Westlake, A.; Wrankmore, M. and Brown, M. A. (2004) case study on the application of disposable technologies in cGMP manufacturing processes for a therapeutic antibody. Annual 2004 ACS meeting, Anaheim CA.
188. Singh, V. (1999) Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology, 30, 140-158.
189. Mikola, M.; Burden, E.: Jug-Dujakovic, M.; Pearre, C.; Herber, W. and Amanulah, A. (2004) Wave bioreactor adenovirus serotype 6 propagation in Per C6 cells: process development. ACS 2004 Ann. meeting, Anaheim CA.
190. Ekstrom, D.; Cheng, W.; Andersson, R.; Mitra, G. and Zhu, J. (2004) Adenovirus Production and Recovery using a Wave™ Bioreactor. ACS 2004 Annual meeting, Anaheim CA.
191. Namdev, P. and Lio, P. (2000) Assessing a disposable bioreactor for attachment-dependent cell cultures. Biopharm, 44-50.
192. Weber, W.; Weber, E.; Geisse, S. and Memmert, K. (2002) Optimization of protein expression and establishment of the wave bioreactor for baculovirus/insect cell culture. Cytotechnology, (38), 77-85.
193. Hami, L.; Chana, H.; Yuan, V. and Craig, S. (2003) Comparison of a static process and a bioreactor-based process for the GMP manufacture of autologous Xcellerated T cells for clinical trials. Bioprocessing Journal, 2, 1-10.
194. Ohashi, R.; Singh. V. and Hammel, J-F. (2001) Perfusion cell culture in disposable bioreactors. ESACT, Tylosan Sweeden.
195. Isett, K.; George, H.; Herber, W. and Amanullah. A. (2007) Twenty-four-well plate miniature bioreactor high-throughput system: assessment for microbial cultivations. Biotechnol. Bioeng., 98(5), 1017-1028.
196. Hanson, M.; Ge, X.; Kostov, Y.; Brorson, K.; Moreira, A. and Rao. G. (2007) Comparisons of optical pH and dissolved oxygen sensors with traditional electrochemical probes during mammalian cell culture. Biotechnol. Bioeng., 97(4), 833-841.
197. Moran, N. (2008) Priced out of the UK market. Nat. Biotechnol., 26, 151-154.